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Integrin a3b1 Potentiates TGFb-Mediated Induction
of MMP-9 in Immortalized Keratinocytes
John M. Lamar1,2, Vandana Iyer1,2 and C. Michael DiPersio1
Transforming growth factor-b (TGFb) signaling pathways regulate a number of keratinocyte functions during
epidermal carcinogenesis and wound healing, including proliferation, survival, and migration. TGFb can induce
expression of the matrix metalloproteinase-9 (MMP-9), which has critical roles in promoting extracellular matrix
remodeling and angiogenesis during tumorigenesis and tissue repair. Integrin a3b1 is a cell adhesion receptor
for laminin-332/laminin-5 with important roles in the survival and motility of epidermal keratinocytes. We
previously reported that a3b1 induces the expression of MMP-9 in immortalized keratinocytes. In this study, we
show that endogenous TGFb is required for maximal MMP-9 expression, and that a3b1 is required for full
induction of MMP-9 protein and mRNA in response to TGFb. This regulation was not observed in non-
immortalized, primary keratinocytes, indicating that coordinate regulation of MMP-9 by a3b1 and TGFb is a
property of immortalized cells. a3b1 did not regulate endogenous TGFb gene expression, TGFb bioavailability,
or TGFb-Smad signaling. However, the combined inductive effects of TGFb and a3b1 on MMP-9 were suppressed
by a Src family kinase (SFK) inhibitor, indicating involvement of a SFK pathway. These findings provide early
evidence of a role for a3b1 in augmenting TGFb-mediated induction of MMP-9 in immortalized or transformed
keratinocytes during skin carcinogenesis.
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INTRODUCTION
Members of the transforming growth factor-b (TGFb) family
regulate diverse cell functions, including differentiation,
proliferation, survival, and migration (ten Dijke and Hill,
2004). TGFb has important, although paradoxical roles in
epidermal carcinogenesis. TGFb acts as a tumor suppressor at
early stages of skin tumorigenesis (Wang, 2001; Zavadil and
Bottinger, 2005). However, it promotes keratinocyte epithe-
lial-to-mesenchymal transition (EMT) and malignant conver-
sion of tumor cells at later stages (Kane et al., 1991; Levine
et al., 1993; Wang, 2001; Han et al., 2005), a function that is
thought to require sustained TGFb signaling through auto-
crine stimulation of TGFb expression (Zavadil and Bottinger,
2005). These paradoxical roles for TGFb suggest a switch in
its function that occurs during tumor progression. Consis-
tently, the repertoire of cellular responses to TGFb changes
dramatically during EMT and tumor progression (Derynck
et al., 2001; Wakefield and Roberts, 2002). Expression of
TGFb by epidermal keratinocytes is also increased during
cutaneous wound healing (Kane et al., 1991; Levine et al.,
1993; Han et al., 2005), where it contributes to the regulation
of keratinocyte motility (Singer and Clark, 1999).
Each of the three mammalian TGFb isoforms, TGFb1, -2,
and -3, is secreted as an inactive complex that contains the
latency-associated protein and latent TGFb binding protein
(Sheppard, 2005). This latent complex is linked to the
extracellular matrix (ECM) through latent TGFb binding
protein (Taipale et al., 1994), and it can be activated through
cleavage by extracellular proteases (Lyons et al., 1990; Sato
et al., 1990; Yu and Stamenkovic, 2000), conformational
changes induced by interactions with thrombospondin-1
(Schultz-Cherry et al., 1995; Crawford et al., 1998), or
binding of integrin avb6 to an arginine–glycine–aspartic motif
on latency-associated protein (Munger et al., 1999; Annes
et al., 2004; Sheppard, 2005). Once activated, TGFb interacts
with type I and type II serine/threonine kinase receptors to
initiate signaling pathways that modulate gene expression.
While many responses to TGFb appear to be mediated
through the Smad family of transcription factors, Smad-
independent mechanisms of TGFb signaling also exist
(Derynck and Zhang, 2003). Indeed, TGFb signaling through
mitogen-activated protein kinases plays important roles in
post-transcriptional mRNA stability (Dibrov et al., 2006).
Thus, cellular responses to TGFb depend on a balance of
transcriptional and post-transcriptional regulation through
both Smads and mitogen-activated protein kinases, and this
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regulation is highly context-dependent (Zavadil et al., 2001;
Derynck and Zhang, 2003; Moustakas and Heldin, 2005;
Zavadil and Bottinger, 2005).
TGFb signaling is often coupled with alterations in cell
adhesion and motility, and TGFb-induced EMT in keratino-
cytes is accompanied by changes in the expression of genes
that are involved in these processes (Zavadil et al., 2001).
One target of TGFb signaling in both normal and transformed
keratinocytes, as well as other carcinoma cells, is the matrix
metalloproteinase-9 (MMP-9)/gelatinase B (Salo et al., 1991;
Weeks et al., 2001; Santibanez et al., 2002; Kalembeyi et al.,
2003; Safina et al., 2007). MMP-9 has critical roles in ECM
remodeling and angiogenesis (McCawley and Matrisian,
2001), and its induction by TGFb is likely to be important
during both skin carcinogenesis and cutaneous wound
healing.
Integrin receptors for the ECM also play important
regulatory roles in epidermal tumorigenesis and wound
healing (Grose et al., 2002; Watt, 2002), and recent studies
have implicated certain integrins in regulating some TGFb-
mediated effects on cell motility and EMT (Bhowmick et al.,
2001; Jeong and Kim, 2004; Kloeker et al., 2004). Integrin
a3b1 is a major receptor for keratinocyte adhesion to
laminin-332/laminin-5 (LN-332) in the cutaneous basement
membrane (Carter et al., 1991; Delwel et al., 1994;
Kreidberg, 2000), and it is implicated in wound re-
epithelialization through its established roles in regulating
basement membrane organization and keratinocyte motility
(DiPersio et al., 1997; deHart et al., 2003; Choma et al.,
2004; Frank and Carter, 2004). a3b1 is also expressed at high
levels in epidermal tumors and other carcinomas where it
may regulate tumor cell invasion and metastasis (Natali et al.,
1993; Bartolazzi et al., 1994; Melchiori et al., 1995; Patriarca
et al., 1998; Lohi et al., 2000; Morini et al., 2000; Felding-
Habermann, 2003). We recently reported that a3b1 induces
MMP-9 expression in immortalized keratinocytes by promot-
ing mRNA stability (Iyer et al., 2005), a mechanism that bears
intriguing similarities to the previously described role for
TGFb in promoting MMP-9 mRNA stability in prostate cancer
cells (Sehgal and Thompson, 1999). Interestingly, MMP-9
induction by TGFb (Sehgal and Thompson, 1999) or a3b1
(DiPersio et al., 2000) was acquired by immortalized or
transformed cells, suggesting that cells undergoing EMT may
activate new pathways that promote MMP-9 expression in
response to integrins and/or growth factors. Although there
are several reports that TGFb regulates motility of keratino-
cytes or carcinoma cells through alterations in a3b1
expression or function (Giannelli et al., 2002; Decline
et al., 2003; Jeong and Kim, 2004), cooperative roles for
TGFb and a3b1 in the regulation of MMP-9 have not been
explored.
Previously, we showed that ablating integrin a3b1
expression by null mutation of the a3 Itga3, gene leads to
greatly reduced levels of MMP-9 mRNA in immortalized
keratinocytes, revealing an a3b1-dependent mechanism of
MMP-9 induction in these cells (Iyer et al., 2005). In this
study, we provide evidence of a role for a3b1 in potentiating
the TGFb-mediated induction of MMP-9. We show that
inhibiting endogenous TGFb with a function blocking anti-
body abrogates MMP-9 mRNA expression in immortalized
keratinocytes that express a3b1. We further demonstrate that
a3b1-dependent MMP-9 expression in these cells is not due
to a3b1-dependent differences in endogenous TGFb gene
expression, TGFb bioavailability, or TGFb-mediated Smad
signaling. Instead, our results show that a3b1 potentiates the
induction of MMP-9 in response to TGFb through a
mechanism that requires Src family kinase (SFK) signaling.
a3b1 and TGFb also cooperatively enhanced MMP-9
induction in response to oncogenically activated Ras, a
known stimulator of MMP-9 gene transcription. These
findings may reflect an important role for a3b1 in augmenting
specific TGFb-mediated cellular responses during epidermal
tumorigenesis or other epidermal remodeling processes that
involve MMP-9.
RESULTS
TGFb promotes MMP-9 mRNA expression in immortalized
keratinocytes
TGFb has been shown to induce MMP-9 expression in
normal human keratinocytes (Salo et al., 1991). Therefore,
we first tested the role of TGFb in the regulation of MMP-9
expression in immortalized mouse keratinocytes (MK cells).
MK cells were cultured on laminin-332-rich extracellular
matrix (LN-332 ECM) for 24 hours in the presence of
increasing concentrations of exogenous TGFb. Treatment
with TGFb caused a dose-dependent increase in MMP-9
mRNA levels, while b-actin mRNA levels remained constant
at all doses tested (Figure 1a). Since epidermal keratinocytes
produce TGFb during wound healing (Kane et al., 1991), we
also tested the effect of inhibiting endogenous TGFb on
MMP-9 mRNA expression. Treatment of MK cells for 24 hours
with an anti-TGFb antibody that neutralizes TGFb function
caused a dose-dependent decrease in MMP-9 mRNA levels
(Figure 1b). As a control, treatment with an isotype-specific
control immunoglobin G at the highest concentration had no
effect (Figure 1b). Approximately 60% inhibition of MMP-9
mRNA levels was achieved by treatment with 30mg/ml anti-
TGFb blocking antibody (Figure 1c). Together, these results
indicate that TGFb promotes MMP-9 mRNA expression in
immortalized keratinocytes, and that endogenous TGFb
function is required for full levels of MMP-9 expression.
We showed previously that a3-null MK cells (MK/
cells), which lack integrin a3b1, show greatly reduced MMP-
9 mRNA expression compared with wild-type MK cells
(MKþ /þ cells), indicating that a3b1 is required for MMP-9
expression (Iyer et al., 2005). To test if exogenously provided
TGFb can induce MMP-9 expression in the absence of a3b1,
MK/ cells were cultured on LN-332 ECM with increasing
concentrations of TGFb. Treatment of MK/ cells with
exogenous TGFb for 24 hours induced a dose-dependent
increase in MMP-9 mRNA, while b-actin mRNA levels were
unaffected (Figure 2a). These findings were confirmed by
quantitative real-time reverse transcriptase PCR (RT-PCR)
(Figure 2b), and they show that exogenous TGFb can induce
MMP-9 mRNA in the absence of integrin a3b1 when it is
present at sufficiently high concentrations.
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It is well established that TGFb can promote post-
transcriptional mRNA stability (reviewed in Dibrov et al.,
2006), and it has been shown to induce MMP-9 mRNA in
prostate carcinoma cells through enhanced mRNA stability
without increasing transcription from the MMP-9 promoter
(Sehgal and Thompson, 1999). Similarly, it has been shown
that TGFb did not stimulate the MMP-9 promoter in some
epidermal cell lines (Santibanez et al., 2002). We used
luciferase reporter assays to show that TGFb failed to induce
transcriptional activity of a 1.9 kb human MMP-9 promoter
fragment (Shimajiri et al., 1999), either in the a3-null MK/
cells or in MK/ cells that were stably transfected with
human a3 integrin (MKa3 cells) (Figure 3a, graph). However,
TGFb did induce endogenous MMP-9 expression above basal
levels in these same cells, consistent with post-transcriptional
induction (Figure 3a, gels). The higher basal level of
endogenous MMP-9 in MKa3 cells is due to a3b1-dependent
induction of MMP-9 mRNA that we described previously
(Iyer et al., 2005). The apparent cooperative effect of TGFb
and a3b1 on MMP-9 protein expression is explored later in
this study (see Figure 7). As a positive control for stimulation
of the MMP-9 promoter, adenoviral expression of an
activated Ras mutant, RasV12, similarly stimulated the
MMP-9 promoter in both MK/ cells and MKa3 cells
(Figure 3b, graph). As expected, this promoter induction was
not accompanied by increased MMP-9 levels in the MK/
cells (Figure 3b, gels), since a3b1 is required for post-
transcriptional stability and subsequent accumulation of the
MMP-9 mRNA transcript (Iyer et al., 2005).
a3b1-dependent MMP-9 expression does not result from
changes in endogenous TGFb gene expression, TGFb secretion,
or bioavailability of ECM-associated TGFb
a3b1 is required for MMP-9 expression in MK cells (Iyer et al.,
2005), and our current results show that blocking endogen-
ous TGFb reduces MMP-9 mRNA in a3b1-expressing MK
cells (Figure 1b and c), while treatment with exogenous TGFb
increases MMP-9 mRNA in a3b1-deficient MK/ cells
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Figure 1. TGFb promotes MMP-9 mRNA expression in immortalized keratinocytes. Immortalized keratinocytes (MKþ /þ cells) were cultured on LN-332
ECM for 24 hours in serum-free medium, then treated with either (a) increasing doses of active TGFb as indicated, or (b) increasing concentrations of anti-TGFb
neutralizing antibody (0, 5, 15, or 30 mg/ml) or control immunoglobin G (30 mg/ml) as indicated. For both (a) and (b), total RNA was isolated and RT-PCR
was performed to assess MMP-9 and b-actin mRNA levels. (c) Quantification of MMP-9 mRNA levels in MK cells cultured in the absence (0) or presence (30)
of 30mg/ml anti-TGFb neutralizing antibody. Average MMP-9 mRNA levels, after normalization to b-actin mRNA, are shown as a percentage of levels in
untreated cells. Data are the mean7SEM; n¼ 3; *Po0.05, t-test.
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Figure 2. Exogenous TGFb induces a dose-dependent increase in MMP-9
mRNA expression independently of integrin a3b1. (a) a3-null MK/ cells
were cultured on LN-332 ECM for 24 hours in serum-free medium in the
presence of increasing doses of exogenous TGFb, as indicated. RT-PCR was
performed to assess MMP-9 and b-actin mRNA levels. (b) MK/ cells were
treated as in (a), and real-time RT-PCR was performed to quantify relative
MMP-9 mRNA levels after normalization to b-actin mRNA.
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(Figure 2). Together, these findings raised the possibility that
a3b1 regulates MMP-9 expression by controlling endogenous
TGFb gene expression. To test this possibility, we compared
TGFb mRNA levels in MKþ /þ cells, MK/ cells, or the
a3-transfected MKa3 cells. When cultured on LN-332 ECM
under conditions where MMP-9 expression is known to be
a3b1-dependent (Iyer et al., 2005), MK cells expressed
similar amounts of TGFb mRNA regardless of a3b1 expres-
sion (Figure 4a and b), indicating that a3b1-dependent MMP-
9 expression is not due to a3b1-mediated differences in TGFb
gene expression.
We next tested whether differential secretion of TGFb into
the culture medium by MKþ /þ cells and MK/ cells
could account for a3b1-dependent MMP-9 expression. First,
we tested if treatment with serum-free, conditioned culture
medium from MKþ /þ cells can induce MMP-9 expression
in MK/ cells. These experiments were performed over a
24-hour treatment period, since experiments in which we
either blocked endogenous TGFb (Figure 1) or added
exogenous TGFb (Figure 2) indicated that this time frame
would be sufficient to see effects on MMP-9 expression.
MKþ /þ cell culture medium failed to induce MMP-9
mRNA in MK/ cells (Figure 5, lane 1), while treatment
of the same MK/ cells with exogenous TGFb induced
MMP-9 mRNA expression (Figure 5, lane 4), indicating that
active TGFb was not present at sufficiently high concentra-
tions in MKþ /þ cell culture medium to induce MMP-9
mRNA. This finding was confirmed using ELISA to quantify
TGFb levels in the culture medium (data not shown), which
showed that the amount of secreted TGFb that had
accumulated within 24 hours from either a3b1-expressing
(i.e. MKþ /þ or MKa3) or a3b1-deficient (i.e. MK/) cells
was at least 20-fold lower than the minimum concentration of
exogenous TGFb (1 ng/ml) that was sufficient to induce MMP-
9 mRNA in the MK/ cells (see Figure 2).
The low level of endogenous TGFb that was detected in
MK cell culture medium is consistent with the fact that most
TGFb is secreted from cells as part of an inactive latent
complex that is covalently associated with the ECM through
latent TGFb binding protein (Sheppard, 2005). It therefore
seemed possible that a3b1 somehow regulates the bioavaila-
bility of ECM-associated TGFb, as has been shown for
integrin avb6 (Munger et al., 1999; Annes et al., 2004;
Sheppard, 2005). To explore this possibility, we exploited
transformed mink lung epithelial cells (MLECs) that stably
express a luciferase reporter gene under control of the TGFb-
responsive plasminogen activator inhibitor-1 (PAI-1) promo-
ter (Abe et al., 1994). Since MLECs are not capable of
activating latent TGFb, luciferase reporter expression in these
cells is a useful readout to assess the level of active TGFb that
is associated with the ECM (Annes et al., 2004).
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Figure 3. TGFb does not induce the MMP-9 promoter in MK cells.
(a) MK/ cells or MKa3 cells grown on LN-332 ECM were transfected with
an MMP-9 promoter/luciferase reporter plasmid and cultured for 48 hours in
serum-free medium in the absence or presence of 10 ng/ml TGFb, as
indicated. (b) MK/ cells or MKa3 cells grown on LN-332 ECM were left
uninfected (RasV12) or infected with RasV12 adenovirus (þRasV12),
then transfected with the MMP-9 promoter/luciferase reporter plasmid and
cultured for an additional 48 hours in serum-free medium. For (a) and (b), cell
lysates were assayed for luciferase expression (arbitrary units). Data are the
mean7SEM; n¼ 3–6 in at least two separate experiments; *Po0.01, one-way
analysis of variance with Newman–Keuls post hoc test. Culture media from
the transfected cells were also collected and assayed for endogenous MMP-9
protein by gelatin zymography (gels).
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Figure 4. TGFb gene expression in MK cells is not regulated by integrin
a3b1. (a) MKþ /þ , MK/, or MKa3 cells were cultured on LN-332 ECM in
serum-free medium for 24 hours, then RT-PCR was performed to assess TGFb
and b-actin mRNA levels. (b) Quantification of TGFb mRNA levels, after
normalization to b-actin mRNA, is shown as a percentage of levels in
MKþ /þ cells. Data are mean7SEM; n¼ 5, from three independent
experiments.
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First, we confirmed that MLECs are responsive to active
TGFb under our experimental conditions. MLECs showed
basal luciferase expression when seeded onto collagen
(Figure 6a, Col). Luciferase expression was robustly induced
in MLECs that were seeded onto collagen that had been pre-
coated with active TGFb (Figure 6a, Col, þTGFb), and this
induction was blocked by the addition of anti-TGFb
neutralizing antibody (Figure 6a, Col, þTGFb, þ anti-TGFb).
Next, we tested for the presence of active TGFb in ECM
substrates deposited by MK cells. When seeded onto collagen
that had been conditioned for 2 days by MKþ /þ cells,
MK/ cells, or MKa3 cells, MLECs showed a basal level of
luciferase expression that was similar to that of untreated
collagen (Figure 6a), indicating the absence of detectable
levels of activated TGFb. As a control, luciferase expression
was induced by each of the three MK-conditioned ECMs if
they were subsequently coated with active TGFb (Figure 6a,
MK ECMs þTGFb), indicating that these ECMs did not
contain inhibitors of TGFb signaling. Consistently, culture of
MK/ cells on LN-332 ECM that had been conditioned by
MKþ /þ cells failed to induce MMP-9 mRNA expression, as
assessed by either semi-quantitative RT-PCR (Figure 6b, lanes
2 and 3) or real-time RT-PCR (Figure 6c). As a control, MKþ /þ
cells continued to express high levels of MMP-9 mRNA when
re-plated onto either their own ECM (Figure 6c) or ECM that
had been conditioned by MK/ cells (data not shown).
Results in Figure 6 indicate that a3b1-dependent MMP-9
expression is not a result of a3b1-dependent differences in the
bioavailability of ECM-associated TGFb.
Integrin a3b1 potentiates induction of MMP-9 mRNA by active
TGFb in immortalized keratinocytes, but not in primary
keratinocytes
Since a3b1 and endogenous TGFb are both required for full
induction of MMP-9 expression in MK cells (Iyer et al., 2005)
(Figure 1), but we found no evidence that a3b1 regulates the
expression or bioavailability of endogenous TGFb, our
findings collectively suggest that a3b1 augments the ability
of MK cells to respond to active TGFb. Indeed, results in
Figure 2 show that exogenously added active TGFb can
induce MMP-9 expression in the absence of a3b1 only when
it is provided at relatively high concentrations. To directly test
whether a3b1 further enhances induction of MMP-9 by
exogenous TGFb, MMP-9 expression was compared between
a3b1-expressing and a3b1-deficient MK cells in the presence
or absence of TGFb. As expected, treatment with 10 ng/ml
TGFb enhanced the levels of MMP-9 protein and mRNA
above baseline levels in both MKþ /þ cells and MK/
cells, as assessed by gelatin zymography and RT-PCR,
respectively (Figure 7a and b). Importantly, however, TGFb-
mediated induction of MMP-9 protein and mRNA was greatly
enhanced in a3b1-expressing MK cells (Figure 7a and b),
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Figure 6. Expression of integrin a3b1 is not correlated with enhanced
bioavailability of TGFb in the ECM. (a) Collagen substrates were conditioned
by MK cells and prepared as described in Materials and Methods. Control
collagen-coated dishes (Col) or MK cell-conditioned ECMs were then
incubated for an additional 24 hours in serum-free medium, plus or minus
10 ng/ml TGFb, as indicated. Anti-TGFb neutralizing antibody (30 mg/ml) was
included where indicated. ECMs were rinsed extensively and assayed for
levels of active TGFb by measuring the induction of the PAI-1
promoter-luciferase reporter gene in MLEC cells, as described previously
(Annes et al., 2004). Data are the mean7SEM; n¼ 3 or more experiments. (b)
MK/ cells were seeded onto LN-332 ECM that was conditioned by MKþ /
þ cells (duplicate lanes 2 and 3) or MK/ cells (duplicate lanes 4 and 5),
then cultured for 48 hours before RT-PCR analysis of MMP-9 and b-actin
mRNA levels. Negative and positive controls, respectively, included
MK/ cells that were seeded onto unconditioned LN-332 ECM in the
absence (lane 1) or presence of 1 ng/ml TGFb (lane 6). (c) Real-time RT-PCR
was performed to quantify MMP-9 mRNA expression in MKþ /þ or
MK/ cells (cells) sub-cultured on LN-332 ECM that was conditioned as
indicated (ECM). As a control, MK/ cells were treated with 1 ng/ml TGFb
(þTGFb). MMP-9 mRNA levels, after normalization to b-actin mRNA, are
indicated as a percentage of the level in MKþ /þ cells cultured on their own
ECM in the absence of TGFb. Data are mean7SEM; n¼ 3; *Po0.01, one-way
analysis of variance with Newman–Keuls post hoc test.
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indicating that a3b1 potentiates the induction of MMP-9 in
response to TGFb. Quantification of the individual and
combined effects of TGFb and a3b1 on MMP-9 mRNA levels
using real-time RT-PCR showed that MMP-9 mRNA was
induced in MK/ cells to similar levels, by either TGFb
treatment or stable expression of human a3 integrin (Figure
7c; compare bars for MK/, þ TGFb and MKa3, TGFb).
However, TGFb and a3b1 cooperated for maximal induction
of MMP-9 mRNA (Figure 7c; see bars for MKþ /þ , þ TGFb
and MKa3, þ TGFb).
Previously, we showed that a3b1-dependent MMP-9
expression is acquired by immortalized keratinocytes (Di-
Persio et al., 2000). Therefore, we next tested whether a3b1
also enhances TGFb-mediated induction of MMP-9 in freshly
isolated, non-immortalized keratinocytes. MMP-9 mRNA was
induced in primary keratinocytes by TGFb concentrations
ranging from 0.5 to 10 ng/ml (Figure 7d, and data not shown).
However, in contrast with immortalized MK cells, the
induction of MMP-9 mRNA by TGFb in primary keratinocytes
was similar in the presence (a3þ /þ ) or absence (a3/) of
a3b1 (Figure 7d), indicating that cooperative effects of TGFb
and a3b1 are associated with the immortalized phenotype.
We next tested whether a3b1-deficient MK/ cells were
generally deficient in TGFb-mediated signal transduction.
Western blot analysis showed that basal levels of TGFb
receptors I and II were similar in MK cells that express or lack
a3b1 (Figure 8a). Furthermore, TGFb receptor function was
intact in both MK/ and MKa3 cells under our experi-
mental conditions, as indicated by similar robust Smad
phosphorylation in response to TGFb treatment (Figure 8b).
Consistently, TGFb enhanced expression of a PAI-1 promoter/
luciferase reporter gene (Allen et al., 2005) to a modest, but
statistically significant and comparable extent in MK/ cells
and MKa3 cells, indicating that TGFb signaling to the PAI-1
promoter, which involves Smads (Dennler et al., 1998), was
not a3b1-dependent (Figure 8c). Taken together, results in
Figure 8 indicate that TGFb-mediated Smad signaling is not
directly involved in a3b1/TGFb-mediated regulation of
MMP-9 expression.
A recent study in breast cancer cells identified Smad-
independent TGFb signaling that occurs through a pathway
that involves Src (Galliher and Schiemann, 2007), and we
showed previously that a3b1 regulates Src kinase signaling in
immortalized MK cells (Choma et al., 2007). Treatment of
MKa3 cells with the SFK inhibitor 4-amino-5-(4-chlorophe-
nyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) completely
abrogated the inductive effect of TGFb on MMP-9 mRNA
expression, indicating a requirement for SFK signaling in this
regulation (Figure 9a). Potent suppression of MMP-9 mRNA
expression by PP2 was confirmed in TGFb-treated MKþ /þ
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Figure 7. The ability of integrin a3b1 to enhance TGFb-mediated MMP-9
induction is acquired by immortalized MK cells. (a–c) a3b1-deficient MK
cells (MK/) or a3b1-expressing MK cells (MKþ /þ or MKa3) were grown
on LN-332 ECM in serum-free medium in the presence (þ lanes) or absence
(lanes) of 10 ng/ml TGFb. (a) Gelatin zymography was performed after
48 hours to assess MMP-9 secretion. Both RT-PCR (b) and real-time RT-PCR
(c) were performed after 24 hours to assess MMP-9 mRNA, or b-actin mRNA
as a control. Results in (a) and (b) are representative of at least three
experiments. Graph in (c) shows relative MMP-9 mRNA levels, after
normalization to b-actin mRNA, compared with MKþ /þ cells in the absence
of TGFb (set at 1.0); data are mean7SEM; n¼ 3. (d) Non-immortalized,
primary keratinocytes were isolated from epidermis of wild-type (a3þ /þ ) or
a3-null (a3/) neonatal mice and cultured in the presence or absence of
TGFb (10 ng/ml) for 24 hours, and MMP-9 mRNA was quantified by real-time
RT-PCR. Graph shows relative MMP-9 mRNA levels (arbitrary units) after
normalization to b-actin mRNA; data are mean7SEM; a3þ /þ , n¼ 10;
a3/, n¼ 4. Inductive effects of TGFb were significant (Po0.001, two-way
analysis of variance), but there were no significant differences in this
inductive effect between a3þ /þ and a3/.
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Figure 8. TGFb-mediated Smad signaling and PAI-1 promoter induction is
intact in a3b1-deficient MK/ cells. (a) Western blots show similar
expression of TGFb receptors I (TGFb RI) and II (TGFb RII) in MK/ cells and
MKa3 cells; keratin 14 (K14) is shown as a loading control. (b) MK/ cells or
MKa3 cells on LN-332 ECM were serum-starved for 24 hours, then treated for
1 hour with TGFb (10 ng/ml) or left untreated, as indicated. Equal protein was
immunoblotted for phosphorylated Smad1/3, or total Smad protein as a
loading control. Results in (a) and (b) are representative of at least three
separate experiments. (c) MK/ cells or MKa3 cells grown on LN-332 ECM
were transfected with a PAI-1 promoter/luciferase reporter plasmid, then
cultured for 24 hours in the presence of absence of TGFb (10 ng/ml), and cell
lysates were assayed for luciferase expression (arbitrary units). Data are the
mean7SEM, n¼ 6 in three separate experiments; *Po0.01, t-test.
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cells by quantitative real-time RT-PCR (Figure 9b). SFK
inhibition also reduced basal MMP-9 mRNA levels in a3b1-
expressing MK cells that were not treated with exogenous
TGFb (data not shown), suggesting that a Src kinase is also
required for maintenance of basal MMP-9 expression by
endogenous TGFb (Figure 1).
TGFb and a3b1 cooperatively enhance the induction of MMP-9
by oncogenic Ras
Cooperative signaling through TGFb and oncogenic Ras is
required for the maintenance of EMT in many epithelial cell
types (Oft et al., 1996; Zavadil and Bottinger, 2005).
Oncogenic activation of Ras leads to the induction of
MMP-9 through transcriptional activation of the MMP-9
promoter (Gum et al., 1996; Sehgal and Thompson, 1999).
We showed previously that a3b1 potentiates the induction of
MMP-9 by RasV12 in immortalized keratinocytes by promot-
ing post-transcriptional mRNA stability, which was necessary
for accumulation of MMP-9 mRNA following RasV12-
mediated transcriptional stimulation (Iyer et al., 2005). Given
that cooperative induction of MMP-9 by a3b1 and TGFb was
acquired by immortalized keratinocytes, we next wanted to
test if TGFb and a3b1 can cooperate to enhance the
induction of MMP-9 by oncogenic Ras. To this end, we
compared the individual and combined effects of a3b1 and
TGFb on RasV12-mediated MMP-9 induction. First, MKþ /þ
cells cultured on LN-332 ECM were infected with RasV12
adenovirus, or left uninfected as a control, then either treated
with TGFb or left untreated. Gelatin zymography showed that
RasV12 and TGFb each independently induced MMP-9
protein levels in MKþ /þ cells, and in combination they
had a greater effect (Figure 10a, lanes 1–4). Similar effects
were seen on MMP-9 mRNA levels (Figure 10b, lanes 1–4).
Assessment of MK/ cells confirmed our previous
findings that efficient induction of MMP-9 by RasV12 was
dependent on a3b1 (Iyer et al., 2005), since RasV12 failed to
induce significant levels of MMP-9 protein secretion (Figure
10a, lane 6) and had a minimal effect on MMP-9 mRNA
levels (Figure 10b, lane 6). As expected, TGFb alone
modestly induced MMP-9 protein and mRNA (Figure 10a
and b, lane 7). Infection of MK/ cells with RasV12, in
combination with TGFb treatment, further enhanced MMP-9
expression (Figure 10a and b, lane 8), demonstrating that
TGFb, like a3b1 integrin, potentiates RasV12-mediated
induction of MMP-9. However, the highest level of MMP-9
induction by RasV12 was observed when both a3b1 and
TGFb were present (Figure 10a and b, lane 4), indicating
cooperative effects between the integrin and growth factor.
DISCUSSION
Studies in cultured keratinocytes have shown that integrin
a3b1 regulates several functions associated with EMT and/or
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Figure 9. SFK activity is required for TGFb-mediated induction of MMP-9.
(a) a3b1-expressing MKa3 cells on LN-332 ECM were pretreated with
serum-free medium containing the SFK inhibitor PP2 (10 mm) or
dimethylsulfoxide (DMSO) only as a control, then cultured for an additional
24 hours in the presence or absence of 10 ng/ml TGFb, as indicated. RT-PCR
was performed after 24 hours to assess MMP-9 mRNA, or b-actin mRNA as a
control. Note that, for this experiment, the PCR cycle number was adjusted so
that basal MMP-9 mRNA levels are just detectable in untreated cells, so that
TGFb-mediated induction is readily evident. (b) a3b1-expressing MKþ /þ
cells were treated with 10 ng/ml TGFb and grown as in (a) in the presence of
PP2, or DMSO as a control, and MMP-9 mRNA was quantified by real-time
RT-PCR. Graph shows MMP-9 mRNA levels in PP2-treated cells as a
percentage of levels in control cells, after normalization to b-actin mRNA.
Data are the mean7SEM, n¼3; *Po0.001, t-test.
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Figure 10. TGFb and a3b1 cooperatively enhance MMP-9 induction in
response to oncogenic RasV12. (a and b) MKþ /þ cells (lanes 1–4) or MK/
cells (lanes 5–8) were grown on LN-332 ECM and either left uninfected (lanes
1, 3, 5, and 7) or infected with RasV12 adenovirus (lanes 2, 4, 6, and 8). Cells
were then cultured in serum-free medium for an additional 48 hours in the
presence (lanes 3, 4, 7, and 8) or absence (lanes 1, 2, 5, and 6) of TGFb
(10 ng/ml). (a) Cell culture medium was collected and assayed by gelatin
zymography for MMP-9 protein levels, and (b) total RNA was isolated and
assayed by RT-PCR for MMP-9 and b-actin mRNA levels. Results are
representative of three separate experiments.
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wound healing, including ECM deposition and organization
(deHart et al., 2003; Hamelers et al., 2005), cell polarization
and migration (Choma et al., 2004, 2007; Frank and Carter,
2004), and cell survival (Manohar et al., 2004). Cooperative
interactions between TGFb and a3b1, or other integrins, have
been implicated in the regulation of motility or invasiveness
of keratinocytes and carcinoma cells (Gailit et al., 1994;
Zambruno et al., 1995; Giannelli et al., 2002; Decline et al.,
2003; Galliher and Schiemann, 2007). In this study, we
provide early evidence of a role for a3b1 in enhancing the
TGFb-mediated induction of MMP-9 gene expression in
immortalized keratinocytes. Our results show that reduced
MMP-9 expression in a3b1-deficient MK/ cells is not due
to a reduction in basal expression of either TGFb (Figure 4) or
of TGFb receptors I and II (Figure 8a). At the same time,
endogenous TGFb was required for full induction of MMP-9
in a3b1-expressing MKþ /þ cells (Figure 1b), but it was not
sufficient to maintain MMP-9 expression in MK/ cells.
Indeed, relatively high concentrations of exogenous TGFb
were required to induce MMP-9 to a detectable level in the
latter cells (Figure 2), and the presence of a3b1 further
enhanced this inductive response (Figure 7a–c). Taken
together, these findings indicate that a3-null MK/ cells
are deficient in a signaling pathway that promotes TGFb-
mediated MMP-9 expression.
It is well established that TGFb is deposited into the ECM
as part of a latent complex that needs to be activated to
initiate a signaling response (Sheppard, 2005). We did not
detect differences in bioavailable TGFb between ECM from
a3b1-expressing MK cells or a3-null MK/ cells, and a3-
null MK/ cells were unable to produce MMP-9 in
response to ECM that was conditioned by a3-positive
MKþ /þ cells (Figure 6). It is unlikely that these results
simply reflect insufficient levels of TGFb in the ECM, since
blocking endogenous TGFb reduced MMP-9 expression in
MKþ /þ cells (Figure 1), while endogenous TGFb secreted
into the culture medium was not sufficiently high in these
cells to induce MMP-9 (Figure 5). Rather, these results suggest
that MK/ cells are unable to increase MMP-9 production
in response to ECM-associated TGFb. Binding of integrin
avb6 to an arginine–glycine–aspartic motif in latency-asso-
ciated protein activates latent, ECM-associated TGFb
(Munger et al., 1999), and av integrins are essential for
TGFb-mediated signaling in vivo (Yang et al., 2007).
However, it is very unlikely that a3b1 functions similarly,
since it binds poorly, or not at all, to arginine–glycine–aspartic
ligands (Hynes et al., 1989; Weitzman et al., 1993; Delwel
et al., 1994), and a similar mechanism for b1 integrins was
not supported (Munger et al., 1999). It is also unlikely that
avb6 has a direct role in a3b1/TGFb-mediated induction of
MMP-9, since TGFb-mediated Smad signaling was intact in
MKa3/ cells under our experimental conditions (Figure 8),
indicating that avb6-dependent TGFb activation is neither
compromised in these cells nor sufficient for induction of
MMP-9. In addition, our finding that a3b1 enhances MMP-9
induction by exogenous, pre-activated TGFb (Figure 7)
suggests that a3b1 contributes to a TGFb signaling pathway
at a point downstream of TGFb activation.
TGFb can signal through Smad-dependent or Smad-
independent pathways (Derynck and Zhang, 2003; Mousta-
kas and Heldin, 2005). Our findings in MK cells suggest that
TGFb induces MMP-9 expression through a non-Smad, SFK-
dependent mechanism (Figures 8 and 9). Together with our
previous report that a3b1 activates Src signaling pathways in
MK cells (Choma et al., 2007), these results suggest that a Src
family member may link a3b1 to TGFb-mediated induction of
MMP-9 mRNA. These findings are intriguing in light of a
recent study in breast cancer cells, which showed that Src-
mediated phosphorylation of the TGFb type II receptor was
required for TGFb to activate mitogen-activated protein
kinase pathways (i.e. p38), but not for activation of Smad
pathways (Galliher and Schiemann, 2007). Future studies will
explore whether similar mechanisms of Src-mediated TGFb
signaling exist in MK cells.
TGFb regulates many genes at the level of post-transcrip-
tional mRNA stability (Dibrov et al., 2006), including MMP-9
in prostate cancer cells (Sehgal and Thompson, 1999). Our
findings that integrin a3b1 also induces MMP-9 mRNA
stability in immortalized keratinocytes (Iyer et al., 2005), and
that neither a3b1 nor TGFb induced the MMP-9 promoter in
these cells (Iyer et al., 2005) (Figure 3), suggest that TGFb and
a3b1 may cooperatively regulate a signaling pathway that
promotes MMP-9 mRNA stability. Cooperative signaling
could occur via interactions of a TGFb receptor complex
with a3b1, as described for other growth factor receptors and
integrins (ffrench-Constant and Colognato, 2004; Guo et al.,
2006). Alternatively, distinct signaling events that are
activated independently by TGFb or a3b1 may converge on
a common intracellular pathway. Extracellular signal-regu-
lated kinase (ERK) is a potential downstream effector of TGFb/
a3b1-mediated signaling that induces MMP-9 expression,
since TGFb activates ERK in cell culture models of EMT
(Zavadil and Bottinger, 2005), and ERK is both activated by
a3b1 and required for MMP-9 expression in MK cells
(Manohar et al., 2004; Iyer et al., 2005). Consistently, a
recent study showed that autocrine TGFb signaling through
the type I receptor ALK5 leads to mitogen-activated protein
kinase/ERK-dependent induction of MMP-9 mRNA in breast
cancer cells (Safina et al., 2007). Furthermore, we previously
showed that SFK signaling is required for a3b1-mediated ERK
activation in MK cells (Choma et al., 2007), suggesting that a
SFK may link a3b1 and TGFb to an ERK signaling pathway
that promotes MMP-9 expression. p38 is another potential
effector for this regulation, since it is involved in TGFb-
mediated EMT (Bakin et al., 2002; Zavadil and Bottinger,
2005), and cooperative interactions between b1 integrins and
TGFb can activate p38 in mouse mammary epithelial cells
(Bhowmick et al., 2001).
a3b1-mediated induction of MMP-9 gene expression is a
pathway that is acquired during keratinocyte immortaliza-
tion, indicating changes in a3b1 function during EMT
(DiPersio et al., 2000). It is well known that TGFb switches
from a tumor suppressor to a tumor promoter during EMT and
skin carcinogenesis (Derynck et al., 2001; He et al., 2001;
Wang, 2001; Wakefield and Roberts, 2002), and TGFb-
mediated induction of MMP-9 was similarly acquired in
582 Journal of Investigative Dermatology (2008), Volume 128
J Lamar et al.
a3b1 and TGFb Cooperatively Regulate MMP-9
prostate cancer cells (Sehgal and Thompson, 1999). In this
study, we showed that cooperative induction of MMP-9 by
a3b1 and TGFb was acquired by keratinocytes that were
immortalized through expression of SV40 large T antigen.
This regulation was not specific to immortalization by large
T antigen, since we have observed similar regulation in
keratinocytes that were immortalized through p53 null-
mutation (J Lamar and CM DiPersio, unpublished). Therefore,
the acquisition of this regulation occurs as part of the
immortalized phenotype, suggesting a signaling switch that
occurs during EMT. It is well established that TGFb and
oncogenic Ras cooperate to maintain EMT in epithelial cells
(Zavadil and Bottinger, 2005). Our results suggest that TGFb
and a3b1 potentiate maximal MMP-9 induction in response
to RasV12, possibly reflecting an important role for coopera-
tion between TGFb, integrin a3b1, and oncogenic Ras in the
maintenance of MMP-9 expression during epidermal tumor
growth and/or invasion.
MATERIALS AND METHODS
Culture of primary keratinocytes and MK cells
Primary keratinocytes were isolated from epidermis of wild-type
(a3þ /þ ) or a3-null (a3/) neonatal mice and cultured as
described previously (DiPersio et al., 1997). MKs were immortalized
by SV40 large T antigen expression as described previously (DiPersio
et al., 2000). The MKþ /þ cell line (MK-1.16) and MK/ cell line
(MK-5.4.6) were derived from keratinocytes isolated from wild-type
or a3-null mice, respectively (DiPersio et al., 2000). MK/ cells
stably transfected with human a3 (MKa3 cells) express high levels of
a3b1 on the cell surface (Iyer et al., 2005). MK growth medium
consisted of Eagle’s minimum essential medium (BioWhittaker,
Walkersville, MD) supplemented with 4% fetal bovine serum
(BioWhittaker) from which Ca2þ had been chelated, 0.05mM CaCl2,
0.4 mg/ml hydrocortisone, 5mg/ml insulin, 2 109 M T3, 10 units/ml
interferon-g (INFg; (Sigma, St Louis, MO), 10 ng/ml epidermal growth
factor, 100 units/ml penicillin, 100mg/ml streptomycin, and
L-glutamine (Invitrogen Corporation, Carlsbad, CA). MK cell lines
were maintained at 331C, 8% CO2, on tissue culture plates coated
with 30 mg/ml denatured rat tail collagen (BD Biosciences, Bedford,
MA). For experiments, MK cells were sub-cultured on LN-332 ECM
prepared from the SCC-25 squamous cell carcinoma line, as
described previously (DiPersio et al., 2000). We showed previously
that a3-null MK/ cells adhere efficiently to LN-332 ECM through
integrin a6b4 (DiPersio et al., 1997, 2000). All experiments and
reagents described in this study were approved by the Institutional
Biosafety Committee of Albany Medical College. All animal studies
were approved by the Institutional Animal Care and Use Committee
of Albany Medical College.
Antibodies and western blotting
MK cells were cultured on LN-332 ECM for 24–48 hours, in the
presence or absence of TGFb as indicated in the figure legends. Cells
were then lysed in cell lysis buffer (Cell Signaling Technology,
Beverly, MA), and protein concentrations were quantified using the
BCA Protein Assay kit (Pierce, Rockford, IL). Equal protein was
assayed by immunoblot using antibodies against the following
proteins: TGFb receptor I (R&D Systems, Minneapolis, MN), TGFb
receptor II (Santa Cruz Biotechnology, Santa Cruz, CA), keratin 14
(Covance, Richmond, CA), phosphorylated Smad1 (Ser463/465)/
3(Ser423/425) (Cell Signaling Technology), and total Smad2/3 (Cell
Signaling Technology).
Assessment of MMP-9 regulation by TGFb
To test if exogenous TGFb promotes MMP-9 expression, active TGFb
(R&D Systems) was added to serum-free cell culture medium for
24 hours at the concentrations indicated in the figure legends. In
some experiments, cells were pretreated for 5 hours with the SFK
inhibitor PP2 (10 mm; Calbiochem, San Diego, CA) or with
dimethylsulfoxide only as a control, as described previously (Choma
et al., 2007), then cultured for an additional 24 hours with TGFb in
the presence or absence of PP2. To test if blocking endogenous TGFb
inhibits MMP-9 expression, cells were cultured for 24 hours in
serum-free medium containing the indicated concentration of pan-
specific TGFb-neutralizing antibody (R&D Systems). In some
experiments, MK cells were also infected with RasV12 adenovirus,
as described previously (Iyer et al., 2005). MMP-9 mRNA or protein
expression was determined by RT-PCR or gelatin zymography,
respectively, as described below.
Assessment of MMP-9 induction by MK-conditioned culture
medium or ECM
To generate MK cell-conditioned media, MKþ /þ or MK/ cells
were cultured at high density on LN-332 ECM in serum-free
medium, and after 24 hours the conditioned medium was collected
and centrifuged to remove debris. MK cell-conditioned medium, or
control serum-free medium, plus or minus 10 ng/ml TGFb, was
added to MK/ cells on LN-332 ECM for 24 hours. Total RNA was
collected and assayed by RT-PCR for MMP-9 and b-actin mRNA, as
described below.
To generate MK cell-conditioned collagen substrate, MKþ /þ or
MK/ cells were cultured in full-growth medium on 12-well plates
pre-coated with 30 mg/ml denatured rat-tail collagen. After 48 hours,
the MK cells were removed using 5mM ethylenediaminetetraacetic
acid, and the remaining ECM was rinsed extensively and incubated
an additional 24 hours in serum-free medium, plus or minus 10ng/
ml TGFb. As a control, unconditioned collagen substrate was
similarly incubated in serum-free medium, plus or minus 10 ng/ml
TGFb. As a readout to detect active TGFb in MK cell-conditioned or
control ECMs, transformed MLECs stably transfected with a reporter
plasmid containing the luciferase gene downstream of a TGFb-
responsive PAI-1 promoter were obtained from Dr Daniel Rifkin and
used as described previously (Abe et al., 1994). Briefly, 5 105 cells
MLECs were cultured on either control or MK cell-conditioned
collagen in DMEM, 10% fetal bovine serum for 24 hours. Where
indicated as a control, function-blocking anti-TGFb antibody was
added to wells 30minutes before seeding of MLECs. Cell lysates
were assayed for relative luciferase activity using the Luciferase
Assay System (Promega, Madison, WI), as described below.
To generate MK cell-conditioned LN-332 ECM, MKþ /þ or
MK/ cells were cultured in full-growth medium on LN-332 ECM,
and after 48 hours the MK cells were removed using 5mM
ethylenediaminetetraacetic acid and the remaining ECM was rinsed
extensively. Fresh MKþ /þ or MK/ cells were seeded onto MK
cell-conditioned LN-332 ECM in full-growth medium and allowed to
recover overnight. MK cells were then rinsed extensively and
incubated in serum-free growth medium, plus or minus 10 ng/ml
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TGFb, for an additional 24 hours. Total RNA was collected and
assayed by RT-PCR for MMP-9 and b-actin mRNA, as described
below.
Gelatin zymography
MK cells were cultured in serum-free medium for 48 hours, and
culture media were collected for gelatin zymography. MMPs were
concentrated from culture media by binding overnight at 41C to
gelatin–agarose beads (Sigma), recovery by centrifugation, and
elution in zymography sample buffer (final: 2.25% SDS, 9%
glycerol, 45mM Tris pH 6.8, bromophenol blue), then resolved by
non-reducing SDS/PAGE on 10% polyacrylamide gels impregnated
with 1mg/ml gelatin (Sigma), as described previously (DiPersio
et al., 2000).
RT-PCR
Total cellular RNA was isolated from MK cells using the Purescript
RNA Isolation kit (Gentra Systems, Minneapolis, MN) or Trizol
Reagent (Invitrogen Corporation), then reverse transcribed to
produce cDNA template using the First-Strand cDNA Synthesis kit
(Promega). PCR reactions were carried out in 12.5 ml PCR REDTaq
ReadyMix (Sigma) with 5ml of cDNA and 0.4 mM of each primer. PCR
primers and conditions for amplification of MMP-9 and b-actin were
described previously (Iyer et al., 2005). For some experiments,
amplification of b-actin was performed using the real-time RT-PCR
primers described below. PCR primers for TGFb were as described
(Romieu et al., 1997), and generate a 200-bp product: forward
primer, 50-ACCGCAACAACGCCATCTAT-30; reverse primer, 50-
GTAACGCCAGGAATTGTTGC-30. PCR conditions for amplification
of TGFb were 941C for 30 seconds, 551C for 30 seconds, 721C for
30 seconds, 26 amplification cycles. PCR products were resolved on
agarose gels, stained with ethidium bromide, and visualized using a
Bio-Rad Gel-Doc 2000. Signals were quantified using Quantity One
software (Bio-Rad, Hercules, CA). For quantitative real-time RT-PCR
analysis of MMP-9 and b-actin mRNA expression, PCR reactions
were carried out in 10 ml IQ SYBR Green Supermix (Bio-Rad) with
5ml of cDNA and 1mM of each primer. Analysis was performed using
MyiQ real-time PCR detection system according to the manufac-
turer’s instructions (Bio-Rad). PCR conditions were 941C for
3minutes, followed by 40 cycles of 941C for 30 seconds, 541C for
30 seconds, 721C for 30 seconds. PCR primers for MMP-9 generate a
67-bp product: forward primer, 50-CAGCTGGCAGAGGCATACTT
G-30; reverse primer, 50-GCTTCTCTCCCATCATCTGGG-30. PCR
primers for b-actin generate a 203-bp product: forward primer, 50-
TGGTGGTACCACCATGTACC-30; reverse primer, 50-AGGGGCCG
GACTCATCGTACT-30. Melting curves were generated for each
reaction product.
Analysis of transfected MMP-9 and PAI-1 promoters
For MMP-9 promoter assays, an MMP-9 promoter/firefly luciferase
reporter plasmid, was a generous gift from Dr Y. Sasaguri (University
of Occupational and Environmental Health, Kitakyushu, Japan) and
contained a 1,868-bp DNA fragment of the MMP-9 promoter region
(1,879 to 12 from the transcription start site) cloned upstream of
the luciferase gene in the pGL3 vector (Promega), as described
previously (Shimajiri et al., 1999). MK cells seeded on LN-332 ECM
were co-transfected with the MMP-9 promoter/luciferase reporter
plasmid and a TK promoter/Renilla luciferase control plasmid
(Promega) at a 50:1 ratio using lipofectamine, then cultured for
48 hours in serum-free medium, plus or minus 10 ng/ml TGFb. As a
positive control for MMP-9 promoter induction, MK cells were
infected with RasV12 adenovirus before transfection, as described
previously (Iyer et al., 2005). For PAI-1 promoter assays, MK cells
were co-transfected with the Renilla control plasmid and a PAI-1
promoter/firefly luciferase reporter plasmid, a gift from Dr P. Higgins
(Albany Medical College, Albany, NY), which contained the PAI-1
promoter (nucleotides 806 to þ 72) cloned upstream of the
luciferase gene, as described previously (Allen et al., 2005).
Transfected cells were then cultured for 24 hours in the presence
or absence of 10 ng/ml TGFb, as described above. Cell lysates were
assayed for luciferase expression using the Dual-Luciferase Reporter
Assay kit (Promega). Luciferase expression was measured in a TD-20/
20 luminometer (Turner Designs, Sunnyvale, CA), and expression
from luciferase reporter plasmids was normalized to that from the
control promoter/Renilla luciferase control plasmid for each sample.
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